Recently, S&P Global officially released its 2026 Sustainability Yearbook (China Edition). Sihuan Pharmaceuticals (0460.HK) was selected again for its outstanding ESG performance (the Company was selected in 2025), earning internationally authoritative certification for its sustainability strength.
The S&P Sustainability Yearbook has rigorous evaluation standards, relying on a professional corporate sustainability evaluation system to comprehensively verify a company’s overall strength from environmental, social, and governance dimensions. It is a highly recognized ESG honor in the domestic capital market. In this year’s evaluation, Sihuan Pharmaceutical scored impressively, outperforming 95% of domestic pharmaceutical peers, and especially ranked among the top in core areas such as innovation and R&D, quality control, business ethics, and compliant operations.
In recent years, Sihuan Pharmaceutical has adhered to a dual-driven strategy of “innovative drugs and medical aesthetics” consistently integrating ESG development strategies into all aspects of corporate operations, building a comprehensive sustainable development governance framework, empowering low-carbon industrial transformation through green production, deeply cultivating innovative R&D, strictly adhering to quality standards, safeguarding public health, and fulfilling public welfare responsibilities. Improve the internal control compliance system to achieve high-quality, sustainable, and coordinated development.
This selection is a full recognition of S&P Global’s ESG governance capabilities and responsible practices by Sihuan Pharmaceutical. In the future, the Company will continue to deepen its ESG system construction, stay true to its original mission, empower the development of the pharmaceutical aesthetics and health industry through innovation, fulfill corporate responsibility through responsibility, and support the Company’s green, compliant, and long-term development.